Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1045 versus blinatumomab in relapsed or refractory Philadelphia-negative CD19-positive B-cell acute lymphoblastic leukemia
NL-OMON61240Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of CN201 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Merck & Co. Primary endpoints: Complete remission within the first 3 treatment cycles, Number of participants with an adverse event and 3 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
CN201
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NL-OMON61240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61240.